INO — Inovio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $92.76m
- $56.08m
- $0.07m
Brief: Inovio Pharmaceuticals Q1 Operating Expenses USD 25.1 Million
Inovio Pharmaceuticals Inc expected to post a loss of 74 cents a share - Earnings Preview
Inovio Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Inovio Pharmaceuticals Inc expected to post a loss of 84 cents a share - Earnings Preview
Inovio Pharmaceuticals Inc expected to post a loss of 84 cents a share - Earnings Preview
Brief: Inovio Pharmaceuticals' Phase 1/2 Study Results Published In Nature Communications
Brief: Immune Response Data For INO-3107 To Be Presented As A Poster At American Association For Cancer Research Immuno-Oncology Conference
U.S. STOCKS ON THE MOVE-Progressive Corp, Elf Beauty, ASP Isotopes
U.S. STOCKS ON THE MOVE-Canadian Solar, Quanex Building, PENN
U.S. STOCKS ON THE MOVE-Canadian Solar, Candel Therapeutics, Upstart Holdings
Inovio Pharma plumbs new lows on stock-and-warrants offering
Brief: Inovio Announces Pricing Of $30 Million Public Offering
Inovio Pharma tumbles on planned stock offering
U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals
Inovio Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Immunology Data Shows INOVIO's INO-3107 Induced Expansion Of New Clonal T Cells That Infiltrate Airway Tissue And Correspond With Reduction Of Surgeries For RRP Patients Observed In Phase 1/2 Trial
Inovio Pharmaceuticals Inc expected to post a loss of $1.15 a share - Earnings Preview
Inovio Pharmaceuticals Inc expected to post a loss of $1.15 a share - Earnings Preview